CytomX Therapeutics, Inc. (CTMX) stock

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30

$2.04+0.00 (0.00%)

Close on Nov 13, 2026Market cap $444.52MP/E –Yield –

CytomX Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

For fiscal 2014 it was $2.99M.

Period	Period end	Value	Change
FY2014	Dec 31, 2014	$2.99M	–

Parsed from the XBRL in CytomX Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CTMX.

Revenue growth-87.7% · median 176.6%

Operating margin-676.5% · median -599.3%

Net margin-609.0% · median -428.7%

Advertisement
300 × 250

See a number that looks wrong?